Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.

Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.

File Thomas M Jr; Jacobs Michael R; Poole Michael D; Wynne Brian

International journal of antimicrobial agents

2002

2002-10

The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant Streptococcus pneumoniae (PRSP) with amoxycillin (+/-clavulanic acid) MICs of

*Treatment Outcome; 80 and over; Adolescent; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use; Amoxicillin/adverse effects/therapeutic use; Bacterial; Bacterial/drug therapy/immunology; Bronchitis/drug therapy/microbiology; Combination/adverse effects/*therapeutic use; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy; Female; Follow-Up Studies; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multicenter Studies as Topic; Pneumonia; Respiratory Tract Infections/*drug therapy/metabolism/microbiology; Streptococcal Infections/*drug therapy/metabolism/microbiology; Streptococcus pneumoniae/*drug effects

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

235–247

4

20